A secretive biotechnology-centered hedge fund bought shares of Kymera Therapeutics after the stock soared to its highest ...

Dupixent For Moderate-To-Severe Asthma Treatment Market Expected To Reach ~$8.1 Billion By 2032. December 13, 2025 7:27 am - The Dupixent market for moderate-to-severe asthma is valued at $3.25 ...

The European Medicines Agency has recommended the approval of GSK's add-on drug to treat asthma and a chronic inflammatory sinus condition, the company said on Friday.

The biotechnology sector is characterized by significant price swings, and Regeneron Pharmaceuticals is currently navigating one such period. Although the co ...

Sanofi (NASDAQ: SNY) is among the cheap healthcare stocks to buy heading into 2026. As of December 7, Sanofi (NASDAQ:SNY) has ...

After a series of unfortunate regulatory rejections and manufacturing issues surfaced, Regeneron’s shares dipped to $483 this ...

So, Regeneron's revenue rose 1.9% from $3.68 billion in Q2 2025 to $3.75 billion, beating consensus estimate by $160 million ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is included among the 14 Best US Stocks to Buy for Long Term. On December 4, ...

Now, the company will aim to show the drug helps patients with eczema and asthma in larger, placebo-controlled trial.

Interestingly, despite the autumn’s upward trend, November’s haul is the first in 2025 that doesn’t outweigh the ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $500.0 and $750.0 for Regeneron Pharmaceuticals, spanning the ...

Canaccord raised the firm’s price target on Regeneron (REGN) to $1,057 from $850 and keeps a Buy rating on the shares. The firm said they expect ...